CTKB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
53.2M
+10.6%
48.1M
+9.1%
44.1M
-29.0%
62.1M
+18.8%
52.3M
Cost of Revenue
22.0M
+11.2%
19.8M
-13.5%
22.9M
-21.8%
29.3M
+18.2%
24.7M
Gross Profit
31.2M
+10.1%
28.3M
+33.3%
21.3M
-35.4%
32.9M
+19.4%
27.6M
Operating Expenses
39.6M
-0.3%
39.7M
+0.1%
39.7M
+3.2%
38.5M
+4.7%
36.7M
R&D
9.4M
-4.0%
9.7M
+1.4%
9.6M
+7.2%
9.0M
+0.1%
9.0M
SG&A
30.3M
+0.9%
30.0M
-0.4%
30.1M
+2.0%
29.5M
+6.2%
27.8M
Operating Income
-8423000
+26.1%
-11400000
+38.3%
-18463000
-230.1%
-5594000
+39.1%
-9192000
EBITDA
-6310000
+32.8%
-9391000
+43.4%
-16598000
-348.8%
-3698000
+49.2%
-7274000
Net Income
-6097000
+49.9%
-12158000
+35.6%
-18866000
+57.2%
-44076000
-704.6%
-5478000
EPS (Basic)
$-0.05
+44.4%
$-0.09
+40.0%
$-0.15
+55.9%
$-0.34
-750.0%
$-0.04
EPS (Diluted)
$-0.05
+44.4%
$-0.09
+40.0%
$-0.15
+55.9%
$-0.34
-750.0%
$-0.04
Shares (Diluted)
130.4M
+0.7%
129.5M
+0.6%
128.7M
+0.4%
128.2M
+0.5%
127.5M
Cytek Biosciences (CTKB) — Financials